Company / Net Income
Inmune Bio, Inc. Net Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$42.1M
FY2025
5-year range
-$42.1M / -$12.1M
FY2021-FY2025
Trend
-40.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$27M to -$42M over the past 2 years.
Based on SEC 10-K filings.
-$42M in FY2025.
Declined from -$27M to -$42M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, net income decreased 40.2% year-over-year.
- Peak net income was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 49.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$42.1M | -40.2% |
| FY2024 | -$30.0M | -9.9% |
| FY2023 | -$27.3M | +10.0% |
| FY2022 | -$30.3M | -150.8% |
| FY2021 | -$12.1M | -57.6% |
| FY2020 | -$7.7M | -823.4% |
| FY2018 | -$831.5K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026